Diamond Blackfan Anemia (DBA) - Epidemiology Forecast - 2036

Diamond Blackfan Anemia (DBA) Insights and Trends

• Diamond-Blackfan Anemia (DBA) is a rare inherited bone marrow failure disorder characterized by selective deficiency of red blood cell production (pure red cell aplasia), leading to severe anemia typically presenting in infancy.
• DBA is primarily caused by mutations in ribosomal protein genes (e.g., RPS19, RPL5, RPL11), which impair ribosome biogenesis and disrupt erythropoiesis. These mutations lead to reduced proliferation and increased apoptosis of erythroid progenitor cells.
• The hallmark clinical feature is macrocytic anemia with reticulocytopenia, often presenting within the first year of life, with symptoms such as pallor, fatigue, and growth retardation.
• Approximately 40-50% of patients exhibit congenital abnormalities, commonly involving:
• Craniofacial anomalies: cleft palate, micrognathia, hypertelorism, flat nasal bridge.
• Musculoskeletal defects: thumb abnormalities (triphalangeal/absent), short stature, upper limb malformations.
• Urogenital abnormalities: renal malformations, structural urinary tract defects.
• Cardiac defects: ventricular septal defect, atrial septal defect, congenital heart anomalies.
• DBA is associated with an increased risk of malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors (e.g., osteogenic sarcoma).
• Diagnosis is based on clinical and laboratory findings, including macrocytic anemia, reticulocytopenia, and normal leukocyte/platelet counts. Elevated erythrocyte adenosine deaminase (eADA) supports diagnosis, while genetic testing confirms ribosomal gene mutations.

DelveInsight's 'Diamond Blackfan Anemia (DBA) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the diamond blackfan anemia, historical and forecasted epidemiology of the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Diamond Blackfan Anemia (DBA) Understanding

Diamond Blackfan Anemia (DBA) Overview

DBA is a rare inherited bone marrow disorder that typically presents in infancy and is characterized by a failure of red blood cell production due to mutations in ribosomal protein genes. It leads to severe macrocytic anemia with symptoms such as pallor, fatigue, poor feeding, and growth delay. Around 40%-50% of patients also have congenital abnormalities, including craniofacial defects, thumb malformations, short stature, and cardiac anomalies. The disease varies in severity and may also be associated with developmental issues and an increased risk of malignancies later in life.

Diamond Blackfan Anemia (DBA) Diagnosis

Diagnosis of DBA is based on clinical presentation and laboratory findings, typically identified in infancy. It is characterized by severe macrocytic anemia with very low reticulocyte counts, while white blood cells and platelets are usually normal. Bone marrow examination shows a marked reduction or absence of erythroid precursors. Elevated fetal hemoglobin (HbF) levels and increased erythrocyte adenosine deaminase (eADA) activity are supportive findings. Confirmation is achieved through genetic testing, which identifies mutations in ribosomal protein genes in the majority of cases.

Diamond Blackfan Anemia (DBA) Epidemiology

Key Findings from Diamond Blackfan Anemia (DBA) Epidemiological Analysis and Forecast

• Among the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of diamond blackfan anemia in 2025, with nearly 6,000 cases. These cases are anticipated to increase by 2036.
• In the United States, the RPS19 mutation accounted for ~25% cases in 2025 among diamond blackfan anemia cases by mutation.
• Among the EU4 and the UK, approximately 25% of diamond blackfan anemia cases in 2025 were reported to be of the craniofacial type, followed by cases with musculoskeletal, urogenital, and other congenital anomalies.
• In Japan, among the congenital anomalies associated with Diamond-Blackfan anemia, craniofacial anomalies were the most prevalent, with almost 50 cases reported in 2025, followed by musculoskeletal anomalies.

Scope of the Report:

• The report covers a segment of a descriptive overview of diamond blackfan anemia, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Diamond Blackfan Anemia (DBA) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up forecasting
• 11-year forecast
• Patient Burden trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of diamond blackfan anemia? What will be the growth opportunities across the 7MM concerning the patient population with Diamond-Blackfan anemia?
• What is the historical and forecasted diamond blackfan anemia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.